An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.

Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.

The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful. 

A team has engineered two stem cell lines into “synthetic T cells” that destroy breast cancer cells in vitro. 

The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas. 

Cellectis goes public for a whopping $228 million—nearly double the value the company filed for in February.

Cancer treatment becomes more and more personal.